June 2, 2014 / 11:45 AM / 4 years ago

MARKET PULSE-American Realty Capital, Broadcom, NPS Pharma, Oil States

U.S. stock index futures were little changed on Monday, with investors finding few reasons to keep pushing shares higher with the Dow and S&P 500 at record levels. Dow Jones industrial average futures were up 0.10 percent at 16,720, S&P 500 futures were up 0.02 percent at 1,921.9 and Nasdaq 100 futures were up 0.11 percent at 3,739.5.

** AMERICAN REALTY CAPITAL HEALTHCARE TRUST INC, Friday close $9.95, +13.07 pct premarket

** VENTAS INC, Friday close $66.8

American Realty Capital Healthcare, a real estate investment trust focused on acquiring medical office buildings, said it would sell itself to rival Ventas in a stock-and-cash deal valued at $2.6 billion. ARC Healthcare said Ventas would pay $11.33 per share, a premium of about 14 percent to the stock’s Friday close.

** BROADCOM CORP, Friday close $31.87, +11.45 pct premarket

The chipmaker said it was looking to sell or wind-down of its cellular baseband business. The company said on Monday that a sale or wind-down of the business would likely save $700 million annually.

** NPS PHARMACEUTICALS INC, Friday close $31.13, +18.86 pct premarket

London-listed drugmaker Shire Plc has secured a $5 billion credit facility for a takeover offer for New-Jersey-based NPS Pharmaceuticals, The Times of London reported on Sunday. Insiders told The Times that an initial approach to NPS by Shire has been rebuffed.

** OIL STATES INTERNATIONAL INC, Friday close $107.58, -42.83 pct premarket

** CIVEO CORP, Friday close $23.06

Oil States said on Monday that it completed the spin-off of its accommodations business, Civeo Corp, by distributing Civeo shares to its shareholders.

To effect the spin-off, Oil States’ shareholders on Friday received two Civeo shares for each Oil States share they held as of May 21.

** OMEROS CORP , Friday close $11.69

Omeros said the U.S. Food and Drug Administration approved its drug for use in cataract and lens replacement surgeries. The company said it plans to launch the drug, Omidria, later this year in the United States.

** BIOTA PHARMACEUTICALS INC, Friday close $2.69

Biota Pharmaceuticals said it plans to cut its workforce by about two-thirds and shut down its Melbourne, Australia facility following the loss of a key government contract.

** ARCH COAL INC, Friday close $3.56

** PEABODY ENERGY CORP, Friday close $16.16


The U.S. power sector will need to emit 30 percent less carbon dioxide by 2030 than it did in 2005, according to new federal regulations - the centerpiece of the Obama administration’s climate change strategy - to be unveiled on Monday.

** PROTECTIVE LIFE CORP, Friday close $52.3, +9.14 pct premarket

Japanese insurer Dai-ichi Life Co is in advanced talks to buy U.S. peer Protective Life in a deal that could be worth over $5 billion, extending a drive to buy assets abroad as an antidote to a weak domestic outlook.

** MARATHON OIL CORP, Friday close $36.66

Energy firm Det norske has agreed to buy Marathon Oil’s Norwegian business for $2.1 billion in cash and has secured the financing needed to pay for its share of the $20 billion Johan Sverdrup field in the North Sea, it said on Monday.

** KKR & Co LP, Friday close $22.73, -0.13 pct premarket

KKR & Co said on Sunday it had decided to terminate a hedge fund that invested in stocks which the private equity firm had launched in 2011 after poaching a team of proprietary traders from investment bank Goldman Sachs Group Inc.

** BOEING CO, Friday close $135.25

Boeing vowed on Sunday to carry out a smooth transition between current and future models of its two most profitable jets - the long-haul 777 and smaller 737 - and dismissed Airbus plans to overhaul its own A330 model.

** JOHNSON & JOHNSON, Friday close $101.46, -0.32 pct premarket

** PHARMACYCLICS INC, Friday close $88.83, +11.05 pct premarket

A new drug for the most common form of leukemia in adults improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday. Ibrutinib, sold by Pharmacyclics and Johnson & Johnson under the brand name Imbruvica, was approved by U.S. regulators for treatment of chronic lymphocytic leukemia in February.

** BRISTOL-MYERS SQUIBB CO, Friday close $49.74

U.S. researchers are finalizing plans to test two immunotherapy drugs made by Bristol-Myers Squibb Co BMY.N on patients newly diagnosed with the most common form of deadly brain tumors in adults.

** ELI LILLY AND CO, Friday close $$59.86

Eli Lilly’s cancer drug ramucirumab modestly extended survival in a large, late-stage study of patients with advanced, nonsmall cell lung cancer who had relapsed following initial treatment, according to data presented on Saturday.

** HECLA MINING CO, Friday close $2.77

** KINROSS GOLD CORP, Friday close $3.78

** ANGLOGOLD ASHANTI LTD, Friday close $15.79

** GOLDCORP INC, Friday close $23.37

** IAMGOLD CORP, Friday close $3.05

** ELDORADO GOLD,Friday close $5.75

Gold fell for a fifth session on Monday, its longest losing streak in seven months, as rallying stock markets diverted interest from bullion, and ahead of the latest European Central Bank policy meeting and key U.S. data this week.

Spot gold was down 0.5 percent at $1,244.20 an ounce at 0939 GMT, while U.S. gold futures GCv1 for August delivery were down $1.30 an ounce at $1,244.70. Among other precious metals, silver was up 0.2 percent at $18.72 an ounce, recovering from Friday’s 11-month low at $18.60.

Compiled by Shubhankar Chakravorty in Bangalore; Editing by Sriraj Kalluvila

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below